Rushi Parikh
Cardiovascular Disease · Torrance, CANPI 1295051928
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.7%), food and beverage and grants — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Nipro Medical Corporation at 36.9% of the total. Reporting peaked in 2024 at $7,340 and has fallen 77.4% since, to $1,661 in 2025.
Across 147 payments — averaging $104.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nipro Medical Corporation$6K
- Abbott$4K
- Shockwave Medical, Inc$1K
- Cathworks, Inc.$1K
- Abiomed$768
- Boston Scientific$745
- plus $2K from 11 others
Across 15 payments — averaging $47,734 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$366K
- Cathworks, Inc.$175K
- Bayer$145K
- Infraredx, Inc.$29K
What the payments were for
- Consulting fees$8,87558%
- Grants$1251%
- Food & beverage$6,39242%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nipro Medical Corporation | 2 | $5,684 |
| Abbott | 56 | $4,330 |
| Shockwave Medical, Inc | 15 | $1,138 |
| Cathworks, Inc. | 3 | $1,031 |
| Abiomed | 16 | $768 |
| Boston Scientific | 13 | $745 |
| Heartflow, Inc. | 2 | $283 |
| Penumbra, Inc. | 2 | $282 |
| Medtronic | 10 | $278 |
| Cardiva Medical, Inc. | 9 | $190 |
| Edwards Lifesciences | 3 | $180 |
| Johnson & Johnson | 1 | $123 |
| Novartis | 2 | $123 |
| Philips North America LLC | 7 | $117 |
| Merck | 1 | $55 |
| Cardiovascular Systems Inc. | 3 | $41 |
| Pfizer | 2 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$1,800
- FFRangio$1,031
- HeartMate Touch$900
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$754
- Impella$566
- COROFLOW$418
- Indigo System$282
- DRAGONFLY OPSTAR$255
- FFRct$225
- GENERAL - THERAPIES$175
- Vascular Lithotripsy$173
- Emerge Push$166
- Edwards SAPIEN 3 Transcatheter Heart Valve$125
- XARELTO$123
How this compares
$15,392 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $53,042 |
| EntrestoSacubitril/Valsartan | 39 | $40,004 |
| FarxigaDapagliflozin Propanediol | 28 | $15,939 |
| Ezetimibe | 55 | $2,301 |
| Rosuvastatin Calcium | 67 | $2,025 |
| Atorvastatin Calcium | 198 | $1,863 |
| Metoprolol Succinate | 123 | $1,829 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 50 | $1,557 |
| ClopidogrelClopidogrel Bisulfate | 90 | $1,461 |
| Amlodipine Besylate | 82 | $882 |
| Carvedilol | 50 | $598 |
| Hydralazine Hcl | 17 | $378 |
| Amiodarone Hcl | 32 | $364 |
| Losartan Potassium | 36 | $347 |
| Metoprolol Tartrate | 49 | $334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $24 | $53,04240 claims |
| NovartisEntresto | $123 | $40,00439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Torrance
- Matthew BudoffTorrance$3.6M
- Ronald OudizTorrance$617K
- William FrenchTorrance$161K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.